Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.63 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782682 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL3777874 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL2717719 | 0.86 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL3772850 | 0.84 | PIK3CD (0.71) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL3776941 | 0.84 | PIK3CD (0.71) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL3776936 | 0.84 | PIK3CD (0.71) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL3785888 | 0.83 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL3779744 | 0.83 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL3783408 | 0.82 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL3775530 | 0.82 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 15/4885PIK3CG 53/4885PIK3CB 35/4885 |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 25/4885PIK3CG 59/4885PIK3CB 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.